Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?

• Published in: The journal of clinical endocrinology and metabolism 2019-01, Vol.104 (1), p.57-73
• Main Authors: Herrera-Martínez, Aura D, Pedraza-Arevalo, Sergio, L-López, Fernando, Gahete, Manuel D, Gálvez-Moreno, María A, Castaño, Justo P, Luque, Raúl M
• Format: Article
• Language: English
• Subjects: Antilipemic agents; Antitumor activity; Apoptosis; Atorvastatin; Cancer; Cell migration; Cell proliferation; Diabetes; Diabetes mellitus (non-insulin dependent); Epidemiology; Ethylenediaminetetraacetic acid; Gene expression; Ghrelin; Health aspects; Metabolic syndrome; Metformin; Molecular modelling; Neuroendocrine tumors; Pleura; Prognosis; RNA; Secretion; Serotonin; Simvastatin; Somatostatin; Statins; Type 2 diabetes
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2018-01455

Biguanides and statins exert beneficial effects on various cancer types. Their precise effects and underlying molecular mechanisms are poorly understood. We analyzed the relationship between metabolic syndrome and histological, epidemiological, and prognosis variables in two cohorts of patients with neuroendocrine tumors (NETs): those with lung carcinoids (LCs; n = 81) and those with gastroenteropancreatic NET (GEP-NET; n = 100). Biguanide and statin antitumor effects were investigated by evaluating proliferation, migration, secretion, gene expression, and involved molecular pathways in BON1/QGP1 cell cultures. Pleura invasion was higher (LCs group; P < 0.05) and tumor diameter tended to be increased (GEP-NET group) in patients with type 2 diabetes (T2DM) than in those without. Somatostatin and ghrelin systems mRNA levels differed in tumor tissue of patients with T2DM taking metformin or not. Biguanides decreased proliferation rate in BON1/QGP1 cells; the effects of statins on proliferation rate depended on the statin and cell types, and time. Specifically, only simvastatin and atorvastatin decreased proliferation in BON1 cells, whereas all statins decreased proliferation rate in QGP1 cells. Metformin and simvastatin decreased migration capacity in BON1 cells; biguanides decreased serotonin secretion in BON1 cells. Phenformin increased apoptosis in BON1/QGP1 cells; simvastatin increased apoptosis in QGP1 cells. These antitumor effects likely involved altered expression of key genes related to cancer aggressiveness. A clear inhibitory effect of biguanides and statins was seen on NET-cell aggressiveness. Our results invite additional exploration of the potential therapeutic role of these drugs in treatment of patients with NETs.